Codiak BioSciences. has been granted a patent for extracellular vesicles (EVs), including exosomes, that carry specific payloads like antigens and targeting moieties. The patent also covers methods for producing and utilizing these EVs in the treatment and prevention of various diseases, including cancer and autoimmune disorders. GlobalData’s report on Codiak BioSciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Codiak BioSciences, Peptide pharmacophores was a key innovation area identified from patents. Codiak BioSciences's grant share as of June 2024 was 10%. Grant share is based on the ratio of number of grants to total number of patents.
Extracellular vesicles for disease treatment and prevention
The granted patent US11992527B2 describes an innovative isolated extracellular vesicle (EV) designed for potential therapeutic applications. The EV is characterized by its unique composition, which includes an antigen fused to either a Scaffold X or Scaffold Y moiety. The patent outlines various configurations for the fusion of antigens, including the possibility of multiple antigens being attached to different scaffold moieties. The antigens can be derived from a wide range of pathogens, including bacteria, viruses, and fungi, with specific examples such as Epstein Barr virus, influenza viruses, and HIV. Additionally, the EV may incorporate a payload, such as an adjuvant or immune modulator, which can be conjugated to its surfaces or encapsulated within its lumen.
Furthermore, the patent details the structural components of the scaffolds, identifying Scaffold X as a prostaglandin F2 receptor negative regulator (PTGFRN) and Scaffold Y as a brain acid soluble protein 1 (BASP1). The claims also extend to pharmaceutical compositions that include these EVs and methods for treating infections, specifically mentioning the treatment of coronavirus infections. This patent highlights the potential of engineered EVs in immunotherapy and vaccine development, emphasizing their versatility in targeting various pathogens and enhancing immune responses.
To know more about GlobalData’s detailed insights on Codiak BioSciences, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
